SIX · LONN.SW
Lonza Group AG
CHF 640.80+CHF 11.00 (+1.75%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
Loading market information…
HKSE · 1548.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 02:19 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Genscript Biotech Corporation’s quoted price sits in the upper half of its reported 52-week range, 25.8% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Genscript Biotech Corporation’s next earnings report is currently expected on Mar 24, 2027, with estimated earnings per share of HK$0.08. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Genscript Biotech Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Mar 10, 2024 | -HK$0.25+36.0% vs estimate | HK$3.50B-3.78% vs estimate |
|---|
| Q2 2023 | Aug 20, 2023 | -HK$0.35 | HK$3.07B-94.26% vs estimate |
|---|
| Q4 2022 | Mar 31, 2023 | -HK$0.34 | HK$2.47B-95.38% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 640.80+CHF 11.00 (+1.75%)
Lonza Group AG’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
₩1,423,000+₩57,000 (+4.17%)
Samsung Biologics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.43% below the high.
€228.40+€7.00 (+3.16%)
Sartorius Stedim Biotech S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
HK$45.08+HK$0.02 (+0.04%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 22.28% below the high.
$376.10+$2.12 (+0.57%)
Charles River Laboratories International, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.93% below the high.
$72.71+$0.02 (+0.03%)
Bio-Techne Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$384.40-$0.72 (-0.19%)
Bio-Rad Laboratories, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.99% below the high.
CN¥44.77-CN¥1.01 (-2.21%)
Joinn Laboratories(China)Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 19.68% below the high.
